RxDoctor Payments Data

Thomas Farchone, MD

Family Medicine · Battle Creek, MINPI 1063476844

Payments from drug & device makers

$1,012in general payments, 2019–2025

Across 69 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$169
  • Novo Nordisk$157
  • Johnson & Johnson$113
  • AbbVie$94
  • AstraZeneca$83
  • Astellas Pharma US Inc$79
  • plus $318 from 11 others

What the payments were for

  • Food & beverage$1,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,012 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$66,382
Medicare patients
171
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide69$101,360
MounjaroTirzepatide29$31,033
JanuviaSitagliptin Phosphate24$30,858
OzempicSemaglutide26$29,902
XareltoRivaroxaban20$28,780
EliquisApixaban23$27,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,952
SymbicortBudesonide/Formoterol Fumarate56$17,032
VraylarCariprazine Hcl12$16,338
MyrbetriqMirabegron12$12,022
LinzessLinaclotide13$10,062
Raloxifene Hcl141$6,699
Metoprolol Succinate259$6,456
DuleraMometasone/Formoterol15$4,849
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$4,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$40$132,39398 claims
MerckJanuvia, Dulera$11$35,70739 claims
PfizerEliquis, Dilantin$14$31,07239 claims
Novo NordiskOzempic$157$29,90226 claims
Johnson & JohnsonXarelto$113$28,78020 claims
AbbVieVraylar, Linzess$94$26,40025 claims
GSKTrelegy Ellipta$23$18,95214 claims
AstraZenecaSymbicort$83$17,03256 claims
Astellas Pharma US IncMyrbetriq$79$12,02212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →